UPMC is investing in and partnering with cancer diagnostics company Cernostics to pursue precision medicine.
Pittsburgh, PA (PRWEB) August 31, 2016
As part of its wide-ranging efforts to better target treatments to patients while reducing unnecessary tests and procedures, UPMC announced today that it is investing in and partnering with Cernostics, an oncology diagnostics company whose unique technology enables so-called “precision medicine.”
Through UPMC Enterprises, the commercialization arm of UPMC, the health system is the lead investor in a $5 million round of funding by Cernostics to help it grow and accelerate its introduction of a new diagnostic test for people with an esophageal condition called Barrett’s Esophagus that can lead to cancer.
“This strategic investment in Cernostics not only gives us a stake in what the company already has developed but will give our physicians and scientists access to Cernostics’ advanced technology platform for potentially developing a wide range of precision medicine tests,” said Tal Heppenstall, president of UPMC Enterprises.